Wordt geladen...
Cancer immune resistance: can theories converge?
Immune oncology (IO) is challenged to expand its usefulness to a broader range of cancers. A second generation of IO agents acting beyond the realm of Checkpoint Inhibitor Therapy (CIT) is sought with the intent of turning immune-resistant cancers into appealing IO targets. The published literature...
Bewaard in:
| Gepubliceerd in: | Emerg Top Life Sci |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Portland Press Ltd.
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7289003/ https://ncbi.nlm.nih.gov/pubmed/33525800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/ETLS20170060 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|